Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel F. Grothey, Eric Van Cutsem, Alberto Felice Sobrero et al. · The Lancet · 2012
Cited by 2,885 works. doi:10.1016/s0140-6736(12)61900-x
Authors
- Axel F. Grothey
- Eric Van Cutsem
- Alberto Felice Sobrero
- Salvatore Siena
- Alfredo Falcone
- Marc Ychou
- Yves Humblet
- Olivier Bouché
- Laurent Mineur
- Antoine Adenis
- Josep M. Tabernero
- Takayuki Yoshino
- Heinz‐Josef Lenz
- Richard M. Goldberg
- Daniel J. Sargent
- Frank Cihon
- Lisa D. Cupit
- Dirk Laurent
References
- The National Comprehensive Cancer Network
- Interpreting the significance of changes in health-related quality-of-life scores.
- EORTC QLQ-C30 Scoring Manual
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
- Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
- Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
- Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
- Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)